Search results

Order by most recent / most popular / relevance

Results: 1-10 of 49

Trade Marks Office outlines relevant principles for objecting to trade marks containing inn stems

Davies Collison Cave
-
Australia
-
January 17 2013

A recent decision of the Australian Trade Marks Office will be welcomed by pharmaceutical companies seeking to register trade marks containing an INN

Astrazeneca successfully protects Crestor patents against generic attack in the Australian pharmaceutical market

Davies Collison Cave
-
Australia
-
May 18 2012

Three Justices of the Federal Court of Australia have now on three separate occasions restrained Apotex's proposed launch of generic versions of Astra's cholesterol reducing statin, "Crestor" in Australia

Pharmaceutical trade marks containing INN stems receive automatic objection in Australia

Davies Collison Cave
-
Australia
-
September 12 2012

The Australian Trade Marks Office has adopted a practice of automatically objecting to trade mark applications for pharmaceuticals, veterinary preparations or pesticides in class 5 that contain an INN stem on the basis that such marks are considered likely to deceive or cause confusion

UCP Gen Pharma's "Revasc" pharmaceutical trade mark to remain on register

Davies Collison Cave
-
Australia
-
March 20 2012

On 15 March 2012, Justice Jessup of the Federal Court of Australia exercised his discretion to allow UCP Gen Pharma's "Revasc" pharmaceutical trade markindicated for use in the prophylaxis and treatment of venous thrombosis for hip and knee operationsto remain on the Register of Trade Marks, notwithstanding the fact that the mark had not been used in Australia during the statutory three year "non use" period

Change of practice in Australia for pharmaceutical trade marks containing INN stems

Davies Collison Cave
-
Australia
-
February 15 2013

We have previously reported on our lobbying efforts regarding the practice of the Australian Trade Marks Office to object to trade mark applications

When (unquantifiable) loss is more another interlocutory battle between originator and generic

Davies Collison Cave
-
Australia
-
September 30 2009

In the recent Federal Court decision of Sigma Pharmaceuticals (Australia) Pty Ltd (ACN 004 118 594) v Wyeth 2009 FCA 595 the patentee, Wyeth, successfully applied for interlocutory injunctive relief restraining Sigma from supplying a generic drug used to treat patients suffering from central nervous system disorders including depression

Victorian biotechnology companies: is your company eligible for government support?

Davies Collison Cave
-
Australia
-
April 26 2012

The Victorian Government provides several programs and funding assistance for Victorian-based companies and organisations looking to commercialise biotechnology in Victoria

Review of pharmaceutical patents system in Australia: issues paper released

Davies Collison Cave
-
Australia
-
November 23 2012

As we previously reported, on 15 October 2012 the Australian Government announced a review into the effectiveness of the pharmaceutical patents system in Australia

Pharmaceutical Patents Review Panel releases "Suggested Issues Paper"

Davies Collison Cave
-
Australia
-
January 4 2013

On 21 November 2012 the Pharmaceutical Patents Review Panel released an Issues Paper entitled "Background and Suggested Issues Paper" to outline the scope

Is a method of treatment of the human body a patentable invention?

Davies Collison Cave
-
Australia
-
February 22 2013

In what will undoubtedly be an important decision for the medical and pharmaceutical industries, the High Court of Australia will this year

next >